Details for Patent: 8,173,168

Title:	Dispersible macromolecule compositions and methods for their preparation and use
Abstract:	A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly suitable for pulmonary delivery for therapeutic and other purposes may be prepared.
Inventor(s):	Platz; Robert M. (Half Moon Bay, CA), Brewer; Thomas K. (Walnut Creek, CA), Boardman; Terence D. (Palo Alto, CA)
Assignee:	Novartis Pharma AG (Basel, CH)
Filing Date:	Sep 28, 2006
Application Number:	11/536,348
Claims:	1. A composition comprising: a plurality of inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles have a rugosity of at least 2, as determined by air permeametry and wherein the composition has an average particle size of less than 10 .mu.m. 2. The composition of claim 1, wherein the rugosity is at least 3. 3. The composition of claim 1, wherein the rugosity ranges from 2 to 6. 4. The composition of claim 1, wherein the rugosity ranges from 4 to 6. 5. The composition of claim 1, wherein the pharmaceutically acceptable carrier comprises a buffer. 6. The composition of claim 5, wherein the buffer comprises sodium citrate. 7. The composition of claim 1, wherein the pharmaceutically acceptable carrier comprises a penetration enhancer. 8. The composition of claim 1, wherein the particles have a moisture content of less than 10 wt %. 9. The composition of claim 1, wherein the particles have a moisture content of less than 5 wt %. 10. The composition of claim 1, wherein the composition has an average particle size of less than 5 .mu.m. 11. The composition of claim 1, wherein the rugosity is at least 3, and wherein the particles have a moisture content of less than 10 wt %. 12. The composition of claim 1, wherein the rugosity is at least 3, wherein the composition further comprises sodium citrate, and wherein the particles have a moisture content of less than 10 wt %. 13. The composition of claim 1, wherein the rugosity is at least 3, wherein the composition further comprises a penetration enhancer, and wherein the particles have a moisture content of less than 10 wt %. 14. A unit dosage, comprising a therapeutically effective amount of the composition of claim 1 within a receptacle. 15. The unit dosage of claim 14, wherein the receptacle comprises a capsule. 16. The unit dosage of claim 14, wherein the receptacle comprises a foil plastic laminate. 17. A unit dosage, comprising between about 0.5 mg and 15 mg of the composition of claim 1 within a receptacle. 18. An inhalation device, wherein the receptacle of claim 14 is within the inhalation device. 19. A composition comprising: a plurality of inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles have a rugosity of at least 2, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry, and wherein the composition has an average particle size of less than 10 .mu.m. 20. The composition of claim 19, wherein the rugosity is at least 3. 21. The composition of claim 19, wherein the rugosity ranges from 2 to 6. 22. The composition of claim 19, wherein the rugosity ranges from 4 to 6. 23. The composition of claim 19, wherein the pharmaceutically acceptable carrier comprises a buffer. 24. The composition of claim 23, wherein the buffer comprises sodium citrate. 25. The composition of claim 19, wherein the pharmaceutically acceptable carrier comprises a penetration enhancer. 26. The composition of claim 19, wherein the particles have a moisture content of less than 10 wt %. 27. The composition of claim 19, wherein the particles have a moisture content of less than 5 wt %. 28. The composition of claim 19, wherein the composition has an average particle size of less than 5 .mu.m. 29. The composition of claim 19, wherein the rugosity is at least 3, and wherein the particles have a moisture content of less than 10 wt %. 30. The composition of claim 19, wherein the rugosity is at least 3, wherein the composition further comprises sodium citrate, and wherein the particles have a moisture content of less than 10 wt %. 31. The composition of claim 19, wherein the rugosity is at least 3, wherein the composition further comprises a penetration enhancer, and wherein the particles have a moisture content of less than 10 wt %. 32. A unit dosage, comprising a therapeutically effective amount of the composition of claim 19 within a receptacle. 33. The unit dosage of claim 32, wherein the receptacle comprises a capsule. 34. The unit dosage of claim 32, wherein the receptacle comprises a foil plastic laminate. 35. A unit dosage, comprising between about 0.5 mg and 15 mg of the composition of claim 19 within a receptacle. 36. An inhalation device, wherein the receptacle of claim 32 is within the inhalation device. 37. A composition comprising a plurality of inhalable particles, each comprising a drug and a pharmaceutically acceptable carrier, wherein the inhalable particles have an average particle size of less than 10 .mu.m and a rugosity of at least 3, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry. 38. The composition of claim 37, wherein the rugosity ranges from 4 to 6. 39. The composition of claim 37, wherein the drug comprises a macromolecule. 40. The composition of claim 39, wherein the macromolecule is selected from proteins, polypeptides, oligopeptides, nucleic acids, and polysaccharides. 41. The composition of claim 39, wherein the macromolecule is selected from calcitonin, erythropoietin (EPO), factor IX, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, growth hormone, heparin, insulin, interferon alpha, interferon beta, interferon gamma, interleukin-2, leutenizing hormone releasing hormone (LHRH), somatostatin analog, vasopressin analog, follicle stimulating hormone (FSH), amylin, ciliary neurotrophic factor, growth hormone releasing factor (GRF), insulin-like growth factor, insulinotropin, interferon beta, interferon gamma, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor (M-CSF), nerve growth factor, parathyroid hormone, thymosin alpha 1, factor IIb/IIIa inhibitor, alpha-1 antitrypsin, anti-RSV antibody, cystic fibrosis transmembrane regulator (CFTR) gene, deoxyribonuclease (DNase), bactericidal/permeability increasing protein (BPI), anti-CMV antibody, interleukin-1 receptor, and interleukin-1 receptor antagonist. 42. The composition of claim 37, wherein the pharmaceutically acceptable carrier comprises at least one member selected from carbohydrates, amino acids, buffers, and salts. 43. The composition of claim 42, wherein the pharmaceutically acceptable carrier comprises at least one member selected from monosaccharides, disaccharides, polysaccharides, and hydrophobic amino acids. 44. The composition of claim 42, wherein the pharmaceutically acceptable carrier comprises at least one member selected from mannitol, trehalose, sodium chloride, sodium citrate, leucine, lactose, raffinose, alanine, and glycine. 45. The composition of claim 37, wherein the particles have a moisture content below 10 wt %. 46. The composition of claim 37, wherein at least 90% by mass of the particles have a size between 0.1 .mu.m and 7 .mu.m. 47. The composition of claim 37, wherein at least 95% by mass of the particles have a size between 0.4 .mu.m and 5 .mu.m. 48. A composition comprising a plurality of inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles have an average particle size of less than 10 .mu.m and a rugosity of greater than 3, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry. 49. The composition of claim 48, wherein the rugosity ranges from 4 to 6. 50. The composition of claim 48, wherein the pharmaceutically acceptable carrier comprises at least one member selected from carbohydrates, amino acids, buffers, and salts. 51. The composition of claim 50, wherein the pharmaceutically acceptable carrier comprises at least one member selected from monosaccharides, disaccharides, polysaccharides, and hydrophobic amino acids. 52. The composition of claim 50, wherein the pharmaceutically acceptable carrier comprises at least one member selected from mannitol, trehalose, sodium chloride, sodium citrate, leucine, lactose, raffinose, alanine, and glycine. 53. The composition of claim 48, wherein the particles have a moisture content below 10 wt %. 54. The composition of claim 48, wherein at least 90% by mass of the particles have a size between 0.1 .mu.m and 7 .mu.m. 55. The composition of claim 48, wherein at least 95% by mass of the particles have a size between 0.4 .mu.m and 5 .mu.m. 56. A composition comprising: a plurality of inhalable particles having a rugosity of at least 2, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry, each of the plurality of inhalable particles comprising: insulin; and a pH adjuster or buffer. 57. The composition of claim 56, wherein the rugosity is at least 3. 58. The composition of claim 56, wherein the rugosity ranges from 2 to 6. 59. The composition of claim 56, further comprising a pharmaceutically acceptable carrier. 60. The composition of claim 59, wherein the pharmaceutically acceptable carrier comprises one or more bulking agents. 61. The composition of claim 60, wherein the one or more bulking agents comprises at least one member selected from mannitol and glycine. 62. The composition of claim 61, wherein the pH adjuster or buffer comprises sodium citrate. 63. The composition of claim 56, wherein the particles have a moisture content of less than 10 wt %. 64. The composition of claim 56, wherein the particles have a moisture content of less than 5 wt %. 65. The composition of claim 56, wherein the composition has an average particle size of less than 10 .mu.m. 66. A composition comprising: a plurality of inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles are made by atomizing a liquid medium comprising the insulin, the pharmaceutically acceptable carrier, and ethanol to form droplets, and drying the droplets in a heated gas stream to produce the inhalable particles, and wherein the particles have a rugosity of at least 2, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry. 67. The composition of claim 66, wherein the rugosity is at least 3. 68. The composition of claim 66, wherein the rugosity ranges from 2 to 6. 69. The composition of claim 66, wherein the pharmaceutically acceptable carrier comprises a buffer. 70. The composition of claim 69, wherein the buffer comprises sodium citrate. 71. The composition of claim 66, wherein the particles have a moisture content of less than 10 wt %. 72. The composition of claim 66, wherein the particles have a moisture content of less than 5 wt %. 73. The composition of claim 66, wherein the composition has an average particle size of less than 10 .mu.m. 74. The composition of claim 66, wherein the composition has an average particle size of less than 5 .mu.m. 75. The composition of claim 66, wherein the pharmaceutically acceptable carrier comprises sodium citrate, and wherein the particles have a moisture content of less than 10 wt %. 76. A method of treating diabetes, comprising: pulmonarily administering to the alveolar regions of the lungs of a subject a therapeutically effective amount of a composition comprising inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles have a rugosity of at least 2, as determined by air permeametry. 77. The method of claim 76, wherein the rugosity is at least 3. 78. The method of claim 76, wherein the rugosity ranges from 2 to 6. 79. The method of claim 76, wherein the rugosity ranges from 4 to 6. 80. The method of claim 76, wherein the pharmaceutically acceptable carrier comprises a buffer. 81. The method of claim 80, wherein the buffer comprises sodium citrate. 82. The method of claim 76, wherein the pharmaceutically acceptable carrier comprises a penetration enhancer. 83. The method of claim 76, wherein the particles have a moisture content of less than 10 wt %. 84. The method of claim 76, wherein the particles have a moisture content of less than 5 wt %. 85. The method of claim 76, wherein the composition has an average particle size of less than 10 .mu.m. 86. The method of claim 76, wherein the composition has an average particle size of less than 5 .mu.m. 87. The method of claim 76, wherein the rugosity is at least 3, and wherein the particles have a moisture content of less than 10 wt %. 88. The method of claim 76, wherein the rugosity is at least 3, wherein the composition further comprises sodium citrate, and wherein the particles have a moisture content of less than 10 wt %. 89. The method of claim 76, wherein the rugosity is at least 3, wherein the composition further comprises a penetration enhancer, and wherein the particles have a moisture content of less than 10 wt %. 90. A method of treating diabetes, comprising: pulmonarily administering to the alveolar regions of the lungs of a subject a therapeutically effective amount of a composition comprising inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, wherein the inhalable particles have a rugosity of at least 2, as determined by BET, centrifugal sedimentary particle size, and pycnometry. 91. The method of claim 90, wherein the rugosity is at least 3. 92. The method of claim 90, wherein the rugosity ranges from 2 to 6. 93. The method of claim 90, wherein the rugosity ranges from 4 to 6. 94. The method of claim 90, wherein the pharmaceutically acceptable carrier comprises a buffer. 95. The method of claim 94, wherein the buffer comprises sodium citrate. 96. The method of claim 90, wherein the pharmaceutically acceptable carrier comprises a penetration enhancer. 97. The method of claim 90, wherein the particles have a moisture content of less than 10 wt %. 98. The method of claim 90, wherein the particles have a moisture content of less than 5 wt %. 99. The method of claim 90, wherein the composition has an average particle size of less than 10 .mu.m. 100. The method of claim 90, wherein the composition has an average particle size of less than 5 .mu.m. 101. The method of claim 90, wherein the rugosity is at least 3, and wherein the particles have a moisture content of less than 10 wt %. 102. The method of claim 90, wherein the rugosity is at least 3, wherein the composition further comprises sodium citrate, and wherein the particles have a moisture content of less than 10 wt %. 103. The method of claim 90, wherein the rugosity is at least 3, wherein the composition further comprises a penetration enhancer, and wherein the particles have a moisture content of less than 10 wt %. 104. A method of delivery of a composition to the lungs of a subject, the method comprising: administering by inhalation a composition in aerosolized form, wherein the composition comprises inhalable particles, each comprising a drug and a pharmaceutically acceptable carrier, and wherein the inhalable particles have an average particle size of 10 .mu.m and a rugosity of greater than 3, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry. 105. A method of delivery of a composition to the lungs of a subject, the method comprising: administering by inhalation a composition in aerosolized form, wherein the composition comprises inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, and wherein the inhalable particles have a rugosity of at least 2, as determined by air permeametry, and wherein the composition has an average particle size of less than 10 .mu.m. 106. A method of delivery of a composition to the lungs of a subject, the method comprising: administering by inhalation a composition in aerosolized form, wherein the composition comprises inhalable particles, each comprising insulin and a pharmaceutically acceptable carrier, and wherein the inhalable particles have a rugosity of at least 2, as determined by BET, centrifugal sedimentary particle size analysis, and pycnometry, and wherein the composition has an average particle size of less than 10 .mu.m.